Find Funding Opportunities

Notice Intent Publish Funding Opportunity Announcement the Blueprint Neuroscience Research: Training Computational Neuroscience, Biology Model Back Again T90/R90) Notice Number: NOT-DA-15-081 Key Dates Release Date: October 9, 2015 Estimated Publication Date Announcement: January 2016   First Estimated Application Due Date: March 2016  Earliest Estimated Award Date:   July 2017 Earliest Estimated Start Date:   August 2017 Related Announcements RFA-DA-11-005  Issued National Eye Institute NEI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Center Complementary Integrative Health NCCIH) Office Behavioral Social Sciences Research OBSSR) Purpose NIH Blueprint Neuroscience Research intends reissue a Funding Opportunity Announcement FOA) the ldquo;Training Computational Neuroscience: Biology Model Back Again T90/R90)” RFA-DA-11-005). Notice being provided allow potential applicants sufficient time develop meaningful training program collaborations will link research training research education responsive applications.  FOA expected be published the end Winter 2016 an anticipated application due date Spring 2016. Awards provide to 5 years support. reissued FOA expected be largely similar the previous versions. Known changes consist revised instructions reflect policy changes recommended the Biomedical Workforce Working Group of the Advisory Committee the Director, NIH, well instructions regarding changes SF 424 application forms. FOA utilize T90/R90 activity code. Brief details the planned FOA provided below. Full details be available the reissued FOA. Research Initiative Details purpose this FOA to establish new research training research education programs computational neuroscience, to support continuation meritorious existing programs, undergraduate predoctoral level students. is intended programs provide research training research education both experimental neuroscience in theories principles the physical, computer, mathematical, engineering sciences are necessary develop models, test experimentally, use experimental data refine models normal disordered neural systems processes. Programs further expected stimulate interactions among training faculty multiple disciplines departments to foster development an integrated curriculum computational neuroscience the applicant institution. Training computational neuroscience the undergraduate level optimal establishing ldquo;pipeline” computational neuroscientists attracting students the quantitative sciences apply disciplines neuroscience research questions early their careers, conversely, undergraduates the biological behavioral sciences acquire sufficient education the quantitative sciences pursue research using computational neuroscience methods. institutional predoctoral program full-time research training support graduate students enrolled a relevant doctoral degree program also expected. predoctoral research training component must include NRSA eligible trainees may also include non-NRSA eligible predoctoral participants students). Trainees must the opportunity carry supervised research training computational neuroscience. primary objective this program must to develop students’ research skills knowledge preparation a research career computational neuroscience. APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: Mimi Ghim, PhD  National Institute Drug Abuse NIDA)  Telephone: 301-402-1918 Email:  ghimm@mail.nih.gov

Notice an Additional Application Due Date PAR-13-343 NeuroNEXT Clinical Trials U01)" Notice Number: NOT-NS-15-042 Key Dates Release Date: September 17, 2015  Related Announcements PAR-13-343    Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice adds additional application due date extends expiration date PAR-13-343 NeuroNEXT Clinical Trials U01)", one funding cycle. Part 1. Key Dates Currently FOA reads: Application Due Date(s) December 2, 2013; April 2, 2014; August 1, 2014; December 2, 2014; April 3, 2015; August 3, 2015; December 3, 2015, 5:00 PM local time applicant organization. Scientific Merit Review February 2014; June 2014; October 2014; February 2015; June 2015; October 2015; February 2016; June 2016 Advisory Council Review 2014; October 2014; January 2015; 2015, October 2015; January 2016; 2016 Earliest Start Date July 1, 2014; December 1, 2014; 1, 2015; July 1, 2015; December 1, 2015; 1, 2016; July 1, 2016 Expiration Date December 4, 2015   FOA reads: Application Due Date(s) December 2, 2013; April 2, 2014; August 1, 2014; December 2, 2014; April 3, 2015; August 3, 2015; December 3, 2015; April 4, 2016, 5:00 PM local time applicant organization. Scientific Merit Review February 2014; June 2014; October 2014; February 2015; June 2015; October 2015; February 2016; June 2016 Advisory Council Review 2014; October 2014; January 2015; 2015, October 2015;  January 2016; 2016; October 2016 Earliest Start Date July 1, 2014; December 1, 2014; 1, 2015; July 1, 2015; December 1, 2015; 1, 2016; July 1, 2016; December 1, 2016 Expiration Date April 5, 2016 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Elizabeth McNeil, MD MSc National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9135 Email: mcneilde@ninds.nih.gov

Notice Correction NOT-NS-15-040 Notice Pre-application Informational Webinar RFA-NS-16-002 NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research Program P50)'" Notice Number: NOT-NS-15-041 Key Dates Release Date:   September 11, 2015 Related Announcements NOT-NS-15-040 RFA-NS-16-002       Issued National Institute Neurological Disorders Stroke NINDS)    Purpose Notice to correct registration email address NOT-NS-15-040 quot;Notice Pre-application Informational Webinar RFA-NS-16-002 NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research Program P50)'" Currently registration email address reads: sieber@ninds.nih.gov corrected registration email address reads: sieberb@ninds.nih.gov  Inquiries Please direct inquiries to: Beth-Anne Sieber, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: nbsp;301-496-5680 Email: sieberb@ninds.nih.gov

Notice Pre-application Informational Webinar RFA-NS-16-002 NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research Program P50)" Notice Number: NOT-NS-15-040 Key Dates Release Date:   September 4, 2015 Related Announcements NOT-NS-15-041 RFA-NS-16-002 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to inform potential applicants RFA-NS-16-002 a webinar provide related information the NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research Program. intent the webinar to provide overview the initiative to address questions pertinent the preparation responsive applications. webinar directed primarily toward applicants the December 15, 2015 application due date; investigators considering future application the NINDS Udall Centers program also welcome participate. webinar optional not required application submission. Webinar Information Date: Monday, September 21, 2015 Time: 2:00pm EDT Duration: 1 hour register the webinar, to submit advance questions, please e-mail sieberb@ninds.nih.gov  Friday, September 18, 2015; please include Udall Webinar" the subject line. Every effort be to answer questions during webinar itself; however, due time constraints responses be provided after webinar concludes. Applicants strongly encouraged discuss proposals the Program Officer early the application development process. Inquiries Please direct programmatic inquiries to: Beth-Anne Sieber, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-5680 Email: sieberb@ninds.nih.gov Please direct review-related inquiries to: Birgit Neuhuber, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-3562 Email: neuhuber@ninds.nih.gov

NINDS Announces Interest Large Randomized Emergency Care Clinical Trials Notice Number: NOT-NS-15-039 Key Dates Release Date:   August 27, 2015  Related Announcements NOT-HL-15-262  PAR-13-278 Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS) announces interest applications large, simple, randomized clinical trials neurologic related emergency care adults, address significant public health issues. trials must take place the pre-hospital and/or emergency department settings. NINDS particularly interested multi-site clinical trial applications simple pragmatic trials assessing novel interventions comparative effectiveness.  funded, proposed clinical trials be implemented a planned trans-federal emergency care network entitled Strategies Innovate Emergency Care Clinical Trials Network SIREN) NOT-NS-15-021, NOT-NS-15-022, NOT-NS-15-023) estimated start date March 2017). Since emergency care stroke incorporated the NIH StrokeNet program PAR-14-220), NINDS interested trials addressing neurologic emergencies than stroke the SIREN program.     Applications emergency care clinical trials should submitted the funding opportunity announcement PAR-13-278, NINDS PHASE III Investigator-Initiated Multi-Site Clinical Trials U01). Potential applicants strongly encouraged contact NINDS further information discussion. Inquiries Please direct inquiries to: Dr. Robin Conwit National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9135 Email: conwitr@ninds.nih.gov

Notice Participation Additional NIH Components PAR-15-292 " Emerging Global Leader Award K43)" Notice Number: NOT-TW-15-004 Key Dates Release Date:   August 26, 2015  Related Announcements PAR-15-292     Issued Fogarty International Center FIC) National Human Genome Research Institute NHGRI) National Institute Dental Craniofacial Research NIDCR) National Institute Environmental Health Sciences NIEHS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) Office Research Women’s Health ORWH) Purpose Notice to inform potential applicants additional NIH components participate Program Announcement PAR-15-292 to detail additional interest NHGRI. following changes been to reflect participation NIDCR, NINDS ORWH this FOA to detail additional interest NHGRI: Part 1. Overview Information Components Participating Organizations Fogarty International Center FIC) National Human Genome Research Institute NHGRI) National Institute Dental Craniofacial Research NIDCR) National Institute Environmental Health Sciences NIEHS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) Office Research Women’s Health ORWH) Part 2. Section 1. Funding Opportunity Description Interests Participating NIH Institutes, Centers Offices: National Human Genome Research Institute NHGRI) interested applications individuals pursuing careers researchers the area the ethical, legal, social implications ELSI) genetics genomics research the of genetics clinical settings.  specific research topic proposed should apply across broad spectrum diseases conditions should be specific just disease, except the extent a particular disease serve a model broader applicability.  Examples topics appropriate exploration be found the ELSI Research Priorities website at: http://www.genome.gov/27543732. NHGRI also support applications individuals are developing methods research resources that support, or conducting basic translational research in: genomic sciences, informatics, implementation genomics clinical care genomic medicine), cost-effectiveness genomic interventions. specific research topic proposed should apply across broad spectrum diseases and health conditions should be specific just disease, except the extent a particular disease serve a model broader applicability.  Projects that capitalize unique opportunities use, models, diseases conditions are difficult study the U.S. because prevalence other factors will considered.  Examples such conditions might include, are limited to, sickle cell disease thalassemias, apoA associated kidney disease, and severe adverse drug reactions higher frequency outside U.S., such Stevens Johnson Syndrome SJS). National Institute Dental Craniofacial Research NIDCR) interested applications a research focus dental, oral, craniofacial conditions occur frequently the LMIC are a high public health burden; research addressing health disparities dental, oral, craniofacial conditions; research achieve national regional goals oral dental health such those articulated the World Health Organization. Examples include, are limited to: working local communities establish best means delivering preventive oral health care; establishing successful approaches deliver fluoride a local population, particularly areas without potable water; studying oral pre-malignant lesions associated betel nut use; studying interplay genes environment dental, oral, craniofacial health leveraging environments specific the country. program these topics responsive goals 2, 3, 4 the NIDCR Strategic Plan http://www.nidcr.nih.gov/research/ResearchPriorities/StrategicPlan/). National Institute Neurological Disorders Stroke NINDS) interested supporting mechanistic, epidemiological, prevention, translational clinical research across spectrum neurological, neuromuscular neurovascular diseases disorders all ages. addition prevalent neurological disorders stroke, NINDS also interested supporting research areas rare neglected neurological diseases are relevant the Low- Middle-Income Countries NINDS Disorder Index http://www.ninds.nih.gov/disorders/disorder_index.htm). Office Research Women’s Health ORWH) mission to improve health women, has strides doing by ensuring women diverse populations included all clinical studies, sex gender influences health disease explored, that women the opportunity advance biomedical careers. ORWH assess applications their ability directly fulfill goals 4.0 6.0 the NIH Strategic Plan Women’s Health Sex Differences Research, can found at: http://orwh.od.nih.gov/research/strategicplan/ORWH_StrategicPlan2020_Vo…. Section VII. Agency Contacts other aspects the FOA remain unchanged. Scientific/Research Contacts: Jean E. McEwen, J.D., Ph.D. National Human Genome Research Institute NHGRI) Telephone: 301-402-4997 Email: mcewenj@mail.nih.gov Jeff Schloss, Ph.D. National Human Genome Research Institute NHGRI) Telephone: 301-496-7531 Email: schlossj@exchange.nih.gov Lynn King, Ph.D. National Institute Dental Craniofacial Research NIDCR) Telephone: 301-594-5006 Email: Lynn.King@nih.gov Claudia S. Moy, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9135 Email: moyc@ninds.nih.gov Jennifer Plank-Blazinet, Ph.D. Office Research Women’s Health ORWH) Telephone: 301-496-8931 Email: Jennifer.plank@nih.gov Financial/Grants Management Contact(s) Diana Rutberg National Institute Dental Craniofacial Research NIDCR) Telephone: 301-504-4798 Email: rutbergd@mail.nih.gov Tijuanna E. DeCoster, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9231 Email: decostert@mail.nih.gov Inquiries Please direct inquiries to: Christine Jessup, Ph.D. Fogarty International Center FIC) Telephone: 301-496-1653 Email: Christine.Jessup@nih.gov

Request Information: Input the Development the Federal Pain Research Strategy Notice Number: NOT-NS-16-038 Key Dates Release Date: August 12, 2015 Response Date: September 18, 2015 Related Announcements None     Issued National Institute Neurological Disorders Stroke NINDS)   Purpose behalf HHS, in response provisions the Patient Protection Affordable Care Act, NIH established Interagency Pain Research Coordinating Committee IRPCC) coordinate pain research efforts within HHS across Federal Agencies. IPRCC developing strategic plan pain research across federal agencies.  panel experts convene provide recommendations key pain research areas move field forward the ultimate goal relieve pain improve pain care through evidence based studies enhancing federal research agenda.  key areas prevention acute chronic pain, acute pain acute pain management, transition acute chronic pain, chronic pain chronic pain management, disparities pain pain care provide framework development the strategy upon important cross-cutting elements be addressed. Background information the IPRCC, membership, responsibilities details the planning process develop research strategy, themes the working groups, cross cutting elements be addressed each working group be found http://iprcc.nih.gov/. Information Requested Request Information RFI) invites public comment input the development the federal pain research strategy.  your comments any all these specific areas, ask you consider broad research opportunities needs could the greatest benefit advancing pain research the ultimate goal relieving pain improving pain care. Such broad research opportunities needs include, are limited to: major challenges opportunities revolutionizing we understand, prevent, assess, diagnose manage acute chronic pain. Transformative areas research where new discoveries related areas research have greatest benefit advancing pain research. Transformative areas research where new discoveries related areas research have greatest benefit developing new therapies pharmacologic non-pharmacologic therapies innovative approaches pain management scientific advances could result a quantum leap the care acute chronic pain conditions. New technical capabilities tools can a significant impact pain research clinical practice the next ten years. potential collaborative efforts between relevant non-pain researchers pain researchers. potential expansion the pain research community. potential collaboration within across federal agencies. role potential federal agencies support pain research expanding enhancing pipeline new basic, translational, clinical researchers. Potential areas Public-Private Partnerships – partnerships will allow federal agencies support pain research work collaboratively both public private entities advance research improve public health. inform development the strategic plan, input being sought broad research opportunities, including those listed above they relate research priorities each the following specific thematic areas across continuum pain for disparities pain pain care, the task force address: Prevention acute chronic pain Acute pain acute pain management transition acute chronic pain Chronic pain chronic pain management Disparities pain pain care To Submit Response Click following link access RFI form submit response: http://iprcc.nih.gov/FPRS/RFI assure consideration, responses must received Friday, September 18, 2015. Responses this RFI voluntary. Any personal identifiers be removed responses compiled. Proprietary, classified, confidential, sensitive information should be included your response. RFI for planning purposes only is a solicitation applications an obligation the part the United U.S.) Government provide support any ideas identified response it. Please note the U.S. government not pay the preparation any comment submitted for use that comment. Inquiries Please direct inquiries to: Linda Porter, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-451-4460 Email: porterl@ninds.nih.gov

Notice Cancelation the Final Receipt Date PAR-13-362 Neurological Sciences Academic Development Award K12)” Notice Number: NOT-NS-15-037 Key Dates Release Date:   August 10, 2015  Related Announcements PAR-13-362     Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform scientific community the cancelation the final application due date PAR-13-362 quot;Neurological Sciences Academic Development Award K12)”. nbsp; Part 1. Key Dates Currently reads: Posted Date September 23, 2013 Open Date Earliest Submission Date) November 11, 2013 Letter Intent Due Date(s) Applicable Application Due Date(s) December 11, 2013, October 12, 2014, October 12, 2015 5:00 PM local time applicant organization. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. AIDS Application Due Date(s) Applicable Scientific Merit Review February, 2014 Advisory Council Review May, 2014 Earliest Start Date July 2014 Expiration Date October 13, 2015 Due Dates E.O. 12372 Applicable now modified read: Posted Date September 23, 2013 Open Date Earliest Submission Date) November 11, 2013 Letter Intent Due Date(s) Applicable Application Due Date(s) December 11, 2013, October 12, 2014 5:00 PM local time applicant organization. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. AIDS Application Due Date(s) Applicable Scientific Merit Review February, 2014 Advisory Council Review May, 2014 Earliest Start Date July 2014 Expiration Date August 14, 2015 Due Dates E.O. 12372 Applicable nbsp; other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Stephen Korn, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-4188 Email: korns@ninds.nih.gov

Notice NINDS Programmatic Priority PAR-13-208 Countermeasures Against Chemical Threats CounterACT) Cooperative Research Projects U01)" Notice Number: NOT-NS-15-035 Key Dates Release Date:   August 6, 2015 Related Announcements PAR-13-208     Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to inform potential applicants PAR-13-208 quot;Countermeasures Against Chemical Threats CounterACT) Cooperative Research Projects (U01)" priority be given research applications clearly describe goal developing or therapeutic candidates is ready advanced development the end the proposed project periods to 5 years).  Projects proposed will given priority should culminate the submission a Pre-Investigational New Drug Pre-IND) Application Package the FDA, should very close securing the data planning needed submission the Pre-IND package.  such, applicants encouraged address regulatory strategy necessary achieve goal. Research supported under FOA to prepare advanced development after filing Pre-IND package.  Most the advanced development activities required regulatory approval include GMP GLP level efforts) not usually covered under FOA, could potentially supported other federal agencies industry once NIH-supported research completed.  HHS advanced development agency relevant this FOA the Biomedical Advanced Research Development Authority BARDA). Once research funded under FOA completed, should the following before exploring possibility additional funding through BARDA advanced development. least lead compound. Lead compounds biologically active compounds hits where affinity, potency, selectivity been established. Efficacy an appropriate animal model Initial pharmacology toxicology studies Stable scalable synthesis the lead compound Preliminary regulatory strategy including Target Product Profile regulatory expertise Commercialization plan other indications applicable Intellectual Property Rights Applications focus specifically the above goal be deemed high programmatic priority. applicants strongly encouraged discuss applications the Scientific/Research contact listed the FOA early the application development process. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-443-8189 Email: jettd@ninds.nih.gov

Notice Programmatic Priority NINDS PAR-15-146 Countermeasures Against Chemical Threats CounterACT) Centers Excellence U54)" Notice Number: NOT-NS-15-036 Key Dates Release Date:   August 6, 2015 Related Announcements PAR-15-146 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to inform potential applicants PAR-15-146 quot;Countermeasures Against Chemical Threats CounterACT) Centers Excellence (U54)" priority be given research applications clearly describe goal developing or therapeutic candidates is ready advanced development the end the proposed project periods to 5 years).  Projects proposed response this FOA will given programmatic priority should culminate the submission a Pre-Investigational New Drug Pre-IND) Application Package the FDA, should very close securing the data planning needed submission the Pre-IND package.  such, applicants encouraged address regulatory strategy necessary achieve goal. Research supported under FOA to prepare advanced development after filing Pre-IND package.  Most the advanced development activities required regulatory approval include GMP GLP level efforts) not usually covered under FOA, could potentially supported other federal agencies industry once NIH-supported research completed.  HHS advanced development agency relevant this FOA the Biomedical Advanced Research Development Authority BARDA). Once research funded under FOA completed, should the following before exploring possibility additional funding through BARDA advanced development. least lead compound. Lead compounds biologically active compounds hits where affinity, potency, selectivity been established. Efficacy an appropriate animal model Initial pharmacology toxicology studies Stable scalable synthesis the lead compound Preliminary regulatory strategy including Target Product Profile regulatory expertise Commercialization plan other indications applicable Intellectual Property Rights Applications focus specifically the above goal be deemed high programmatic priority. applicants strongly encouraged discuss applications the Scientific/Research contact early the application development process. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-443-8189 Email: jettd@ninds.nih.gov